DEALS
Zhong Lun Assists Hisky Medical with Series D Financing
Zhong Lun Assists Hisky Medical with Series D Financing
Wuxi Hisky Medical Technology Co., Ltd. (“Hisky Medical”) has recently completed its Series D financing of over CNY 100 million from investment led by Riverhead Capital, with participation from Hunan Pharmaceutical Development Fund and Guangzhou International Bio Island Life Science Innovation and Entrepreneurship Investment Fund. The proceeds will be primarily used for research and development of the investee’s products, commercial promotion, etc., with a view to enhancing product competitiveness and meeting rapidly growing market demands.
As Hisky Medical’s legal counsel, Zhong Lun played an integral role in all aspects of this financing round, providing comprehensive legal support. The project was led by partner Heng Ding. Members of the team also included Xiaoyu Liu, Wenjun Lu, and other associates.
Hisky Medical is an innovative medical technology company focusing on providing non-invasive diagnosis and management solutions for liver, digestive, breast, and other diseases. The company has launched a lineup of core brand products, including the iLivTouch® Non-Invasive Liver Detection System, CelTouch® Confocal Microprobe Imaging Device, and EQTouch® High-End Ultrasound Platform, relying on its industry-leading acoustic and optical technology platforms. These products have obtained overseas market certifications from regulators, including the US FDA, EU’s CE, Japan’s PMDA, Australia’s TGA, South Korea’s KFDA, and Russia’s RZN, among others. T products are widely used for non-invasive screening, diagnosis, and post-diagnosis management in areas including liver, digestive, physical examinations, endocrinology, and respiratory care, benefitting millions of patients in over 60 countries and regions worldwide.
